Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enicepatide in Obesity or Overweight with Comorbidities
NCT06525935Phase 2Completed
- Sponsor
- Carmot Therapeutics
- Start
- Aug 2024
- Primary completion
- Dec 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of zilebesiran in obesity, sponsored by Carmot Therapeutics. Started Aug 2024; status: completed.
02
Drugs
zilebesiran
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06525935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06525935.